Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.05 and .06 is right there....check the L2 on otcmarkets.com.
COME ON POWER HOUR!
They're already effective and safe in a whole range of conditions, ailments, diseases, and treatments.
Whenever the FDA wakes up will be the question. USA is always years behind in this regard.
Clearly the case is NOT closed, as it being argued by the company, and countless others.
That's why it's "IMO".
It is wanted and NEEDED by the general public who seek CURES instead of DRUG treatments.
Way of the future.
Get on board.
300K shares takes us to 10c
NO WALLS!
Legal defense fund
In the United States, a legal defense fund (or LDF) is an account set up to pay for legal expenses, which can include attorneys' fees, court filings, litigation costs, legal advice, or other legal fees. The fund can be public or private and is set up for individuals, organizations, or for a particular purpose. These funds are often used by government public officials, civil rights organizations, and public interest organizations.
Legal defense funds often have large membership counts where the members contribute to the fund. The fund sometimes is or operates like a law firm, where teams of attorneys provide legal services through litigation.[1] Contrary to the name, attorneys working for legal defense funds both file and defend lawsuit. Unlike legal financing from legal financing companies, legal defense funds provide a separate account for litigation rather than a one-time cash advancement, though both are used for purposes of financing litigation and legal costs.
THIS IS THE FUND SET UP TO PROMOTE AND SUE THE FDA FOR CLASSIFYING SVF AS A DRUG.
https://futurism.com/rapidly-manufacture-stem-cells-fda-approved/
Another RECENT article FDA approving stem cell manufacture.
https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm393030.htm
From the FDA WEBSITE... "THEE" FDA.
Adult Stem Cell Research Shows Promise
dated January 4, 2018.
Animal Stem Cell Therapy Market Research – Industry Analysis, Growth, Size, Share, Trends, Forecast to 2022
U.S STEM CELL
https://www.satprnews.com/2018/02/21/animal-stem-cell-therapy-market-research-industry-analysis-growth-size-share-trends-forecast-to-2022/
I am good friends with Mike Johnson of the Cinci Bengals & Jermaine Gresham of the Arizona Cardinals and I spoke with them both about stem cell therapy & US stem cell at Mike’s bday gathering yesterday! They both said that they themselves, teammates or family have used stem cell therapy as it is gaining steam in the sports medicine world! Now if I’m working on selling USRM to Jermaine as an investor ;) we’ll see how it goes!
Just my opinion but I think ANY AND ALL signs of adaption of stem cell therapy is good for USRM!! The more accepted and advertised Stem Cell therapy is, the better for the entire industry! Including the company that’s sold over 10,000 adipose stem cell kits and trained over 700 physicians! :)
Great news!!! To see specifically ADIPOSE STEM CELLS being used in other states and seing that IT WORKS for people is amazing! These are the steps needed for this procedure to go mainstream!!
Check out this video from a DR In UTAH!! More ADIPOSE!
http://www.good4utah.com/news/midday/stem-cell-therapy-treats-ailments-in-the-body-due-to-aging-and-other-common-problems/932068032
I would be more than satisfied to see this thing hit $3.00 in 2018
Lots in our favor (RTT, Adipocell, New Clinics, Trainings, SVF Safety Study) but still lots of resistance from big pharma and the FDA.
Hopefully us being out of debt will also be helpful to us getting into dollar land this year Fingers crossed.
Haaaa!! I figured it out. If you are not signed into your count it won’t show you news on the ticker!!!
My mistake guys, news still posted!
Woah woah woah guys. Definitely not trolling. If it's in your Etrade news then my mistake. Its just no longer on my app and if you go to the etrade website and go the USRM page, it says "no news for US Stem Cell inc"
I'm definitely long here, no bash/troll.
Blessed to be here. U$RM
It does not make or break the stock but getting the news onto the trade platforms (Fidelity,TD Ameritrade, Etrade) has been something people on the board have been screaming for and it's a big victory for the USRM supporters and the company. So to finally get news on Etrade this am and to see it deliberately taken down is disappointing. The news being on the trade platforms have definitely played some role into the recent plus in pps.
ETRADE DELETED THE NEWS
I really hate to see this. It was the first piece of news that it posted under the USRM ticker name. Now when you go look for it, it is gone but I KNOW I saw it this am.
Someone(s) is deliberately doing this. Frustrating.
http://www.businesswire.com/news/home/20171128005819/en/Degenerative-Disc-Patients-Significantly-Improve-USRM%E2%80%99s-AdipocellTM
MIAMI--(BUSINESS WIRE)--U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Chief Science Officer Dr. Kristin Comella will present clinical data demonstrating safety and efficacy of its proprietary AdipocellTM therapy in treating degenerative disc disease — a condition that affects more than 65 million Americans annually1 — at the Annual Meeting for International Federation for Adipose Therapeutics and Science (IFATS).
Dr. Comella, who is a global leader in the development of revolutionary holistic stem cell therapies, will discuss her paper “Effects of the Intradiscal Implantation of Stromal Vascular Fraction Plus Platelet Rich Plasma in Patients With Degenerative Disc Disease,” on Thursday, November 30, 5:30 p.m., at the Lowes Hotel Miami Beach. Dr. Comella’s presentation will also be live streamed at www.facebook.com/comella.stem.cell/.
The study, which included 15 patients with degenerative disc disease, featured the use of USRM’s proprietary AdipocellTM therapy following a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue. AdipocellTM kits and enzyme were used to separate and isolate a patient’s own stromal vascular fraction (SVF) which was then delivered into the disc of patients.
Patients were then monitored for 6 months for adverse events, range of motion, visual analog scale (VAS), present pain intensity (PPI), Oswestry Disability Index (ODI), Beck Depression Inventory (BDI), Dallas Pain Questionnaire and Short Form (SF)-12 scores. Safety events were also monitored, for a 12-month period.
The procedure demonstrated a strong safety profile with no severe adverse events (SAEs) or complications linked to the therapy they received, and no incidences of infection. Patients who participated in this study experienced statistically significant improvements in several parameters including flexion, pain ratings, VAS, PPI, and short form questionnaires. In addition, both ODI and BDI data was trending positive and a majority of patients reported improvements in their Dallas Pain Questionnaire scores. More importantly, patients overall were pleased with treatment results.
“We are seeing so many advancements in regenerative therapy as a result of the application of stem cells from adipose tissue, and the possibilities are endless,” said Dr. Comella, who co-authored the study along with two colleagues. “We are at a time in history where the potential for effective, regenerative medicine from autologous, stem cell therapy is exploding. At USRM, we are pioneering these new therapies for patients and we continue to publish first in man studies like this one.”
IFATS is a non-profit scientific society currently dedicated to scientific areas of interest related to facilitating the development of treatments for excess body fat, the generation of new fat tissue for reconstruction after cancer or birth-related defects and the use of adipose tissue as a source of mesenchymal stem cells that have the potential to regenerate and repair different body tissues.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician/veterinary training and certification and stem cell products and protocols. USRM also provides stem cell banking for patients and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Not sure why. I use a Microsoft pro but the link works fine on mine. Once I click it, it takes me directly to the guestbook page.
Maybe try another computer or tablet.
"We've hired a large legal firm named Venable in Washington DC" - Kristin Comella CSO of US Stem Cell
At the “32:09” mark of the video:
http://www.brainshark.com/Stemlogix/vu?pi=zHXzNfGQxz5OLvz0
https://venable.com/washington-dc/
My opinion but one could deduce that this is the firm that CEO Mike mentioned in the Blog post today.
MUST READ: After some heavy research I came across some information that the firm that was hired is the highly respected Venable law group.
Below are some key links to the firms website.
Lawyers working on the case for Us Stem Cell includes a former lawyer for the Department of Justice who has represented the FDA on multiple occasions (FDA does not have own legal team) as well as a former big pharma lawyer as well.
https://www.venable.com/food-and-drug-law-practices/
https://www.venable.com/drugs-medical-devices-biologics/
Below is an important video that most need to watch. It is of Comella speaking on regulations with the FDA and more importantly she speaks about the inspection from the FDA in length. Very good video, very informative.
To watch the video you have to register with an email address but it's easy. Once done, on the left side of the screen there will be numbered videos.
Video only works on computer, not mobile.
http://www.brainshark.com/Stemlogix/vu?pi=zHXzNfGQxz5OLvz0
Video #39 "October 2017 FDA regulations and recent developments"
at the 30:00 mark Comella speaks about the FDA inspection in length as well as Law firm.
Nov 21, 2017
http://www.nasdaq.com/press-release/us-stem-cell-responds-to-fdas-regenerative-medicine-guidelines-20171121-00606
“The second draft guidance describes the expedited programs that may be available to sponsors of regenerative medicine therapies, including the new Regenerative Medicine Advanced Therapy (RMAT) designation created by the 21st Century Cures Act, Priority Review, and Accelerated Approval. In addition, the guidance describes the regenerative medicine therapies that may be eligible for RMAT designation - including tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, as well as gene therapies that lead to a durable modification of cells or tissues (including genetically modified cells). USRM intends to take full advantage of this RMAT opportunity and join strategic partners to apply for consideration of its MyoCell product for heart failure patients.
Based on these draft guidance documents, the FDA will continue to require a robust clinical trial program for these products which typically costs hundreds of millions of dollars and years of studies. USRM has spent more than $100 million over two decades on both preclinical (animal) and clinical (human) trials using its MyoCell™ product. The trials published to date show culture-expanded autologous stem cells directly injected into the heart can provide benefit to congestive heart failure patients. USRM is actively seeking strategic partners to pursue commercialization of the MyoCell product and finalize RMAT designation based on the draft guidelines published.”
The news today was amazing. Not only are the going to comply with whatever guidelines the FDA sets, it looks like they also may be helping the FDA understand everything there is to know about SVF stem cells for future acceptance of the procedure.
More importantly Myocell could easily bring in 1 billion in valuation and to see that they will be pursuing now that guidelines are set and to see that they are interested in partnering means they’d like to see it happen in the near-midterm future.
One thing that is clear to me is that Reuters, CNA & Seeking Alpha must be accepting some type of payoff because they never mention usrm when some of this news is amazing not only for the company but for the sector. You’d think someone other than yahoo news & baystreet would be on top of these stories.
All in all I’m sticking around to see the fireworks go off as the stage is set here for a big run. All that’s needed now is the volume!
Thats not true. USRM not mentioned in article.
1. I believe we will have an announcement Monday or Tuesday (they like dropping news on Tuesdays apparently) regarding they’re next move with the FDA’s new guidelines. :)
2. It’s funny how all these new articles take the open chance to trash US STEM CELL and Comella about the blinded ladies but don’t emphasize that the ladies had a detieriating eye disease already and were ALREADY going blind and that US STEM CELL was tying to help save they’re eyesight. The intentional bash is clear as day now.
3. Correct me if I’m wrong but it seems the FDA is only concerned with two things: the first being fat injections being put into places like the nervous system, lungs etc without they’re approval (Myocell)
And with clinics using SVF treatments without they’re permission. But if my understanding is correct about adipose stem cells, they can still do regular adipose fat stem cell injections..just not SVF. So if they just stuck with adipose until they get some type of approval to use SVF and seek approval before they continue to market Myocell, then US STEM CELL shouldn’t be bothered by the FDA again. If I’m wrong help me understand.
“Cells may be rinsed or concentrated by spinning in a centrifuge, but manipulation such as multiplying the cells in lab culture is prohibited.“
http://www.philly.com/philly/health/some-stem-cell-therapies-would-skip-usual-fda-rules-under-new-guidelines-20171116.html?mobi=true
If I recall correct..all Comella & US Stem Cell clinic does is take the fat cells, spin in centfrifuge & then place back into the patient. Same day.
Well..that should settle that debate :)))
How is news “way overdue” from USRM?
Just released ANOTHER great Q & reduced debt
Just reviled the # of clinics using they’re technology
FDA dropped huge news today
The future looks bright here. Just waiting on confirmation of RMAT reapplication and we’re off.
Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report 2017 - Research and Markets
Top Companies:
Mesoblast
Regeneus
U.S. Stem Cell
Anterogen
Asterias Biotherapeutics
http://www.businesswire.com/news/home/20171103005597/en/Stem-Cell-Therapy-Osteoarthritis---Pipeline-Analysis
15 cell therapies in phase 3 Clinical Trials
Myocell
https://www.cirm.ca.gov/sites/default/files/files/agenda/Fifteen_Cell_Therapies_PhaseIII_Clinical_Trials.pdf
I’m in!!!!